Re: Confidential: Early detection of Ebola

Dear Anthony,

I really appreciate your willingness to find a potential pathway to Bil= Gates and the Gates

Foundation.

By way of introduction, I have been a Professor at Weill-Cornell for th= last 30 years, and am best known for having invented the Ligase C=ain Reaction (ICR) and the Universal Array. I hold 46 issued US p=tents, a number of which have led to commercial tests to diagnose genetic diseases (i.e. cystic fibrosis, MLPA tests, C0=NSR for NIPD of trisomy), and identify diseases using DNA microarrays a=d targeted Next-Gen sequencing. Earlier this year, I receiv=d the IFCC Award for Significant Contributions in Molecular Diagnostic=.

I have been collaborating with Dr. Linnie Golightly of our Center for G=obal Health/Infectious Disease Division for the past decade, work=ng together closely to develop multiplexed PCR-LDR assays for Category=A Biothreat agents, including all the major viral hemorrhagic fever viruses (VHF; ebolavirus, marburgvirus Crimean Congo=nbsp;hemorrhagic fever virus, Lassa fever virus, Rift Valley fever vir=s, Dengue virus, and Yellow fever virus). (Kindly see belo= abstract of manuscript just being submitted). In addition, in collaboration with Professor Soper at UNC, we have been building =icro-fabricated devices to rapidly detect pathogens.

Most recently, we have begun designing micro-fabricated devices that wi=l allow for electronic detection, obviating the need for expensiv= hardware used in most fluorescent detection schemes (i.e. Taqman assa=s). As such, we are poised to combine these technologies for rapidly identifying and providing quantitative viral load for=all the VHF, Variola, Malaria or other Category A pathogens directly f=om a drop of blood, with the next level of such devices suitable f=r working in developing countries, and may be powered and run by a cell phone or smart device.

• Current CDC approved EZ1-RT-P=R Taqman assay has LOD of 5,000 PFU/ml. This works when patient is&nbs=;febrile, i.e. has overt symptoms and may be contagious.

issue.

• Next level of assay needs to b=> 100-fold more sensitive. We know how to address this

• This would allow for identifi=ation of individuals with early viral replication in their blood •=94before they are contagious, so they may be isolated, and further,&nb=p;early detection may improve outcomes.

Would your contacts be able to help us, so in turn we may help protect o=r country?

Most appreciated,

Francis & Linnie

Dr. Francis Barany
Dept of Microbiology & Immunology
Box 62 Rm B-406
Weill Cornell Medical College

Linnie Golightly, MD
Associate Professor of Clinical Medicine
and Microbiology & Immunology
Center for Global Health
Division of Infectious Diseases
Weill Cornell Medical College

Hi Jeffrey,

=ny interest in helping on this. I know last time you and Francis did not hi= it off. Nevertheless he has been successful as a scientist and is really n=t a "people' person.

He claims he can devel=p the tools to diagnose Ebola before it becomes symtomatic.

Anthony Barrett

ill=try, also i started the conversatoin with mark about splitting u= the interest, he is open to the idea, but wanted someone=smart to advise. that meanss he does't want to pay for advice.

Thanks for your help

Anthony Barrett